Biocoll Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 9 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -44.00%
- Profit Growth -48.10%
- Ebitda -45.81%
- Net Worth 53.24%
- Total Assets -1.47%
About Biocoll Pharmaceuticals
Biocoll Pharmaceuticals Private Limited (BPPL) is a Private Limited Indian Non-Government Company incorporated in India on 18 April 2015 (Nine years and ten months 8 days old ). Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Saini Jitender and Poonam serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999DL2015PTC279199
- Company No.
279199
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Apr 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Biocoll Pharmaceuticals Private Limited offer?
Biocoll Pharmaceuticals Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Dietary Supplements.
Who are the key members and board of directors at Biocoll Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Poonam  | Director | 18-Apr-2015 | Current |
| Saini Jitender | Director | 01-May-2018 | Current |
Financial Performance of Biocoll Pharmaceuticals.
Biocoll Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 44% decrease. The company also saw a substantial fall in profitability, with a 48.1% decrease in profit. The company's net worth Soared by an impressive increase of 53.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Biocoll Pharmaceuticals?
In 2023, Biocoll Pharmaceuticals had a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Brendan Pharma Private LimitedSaini Jitender is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Biocoll Pharmaceuticals?
Unlock and access historical data on people associated with Biocoll Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biocoll Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biocoll Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
